Compare Quest Diagnostics Inc (DGX) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Quest Diagnostics Inc trades at $204.4 (market cap $22.80B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.82. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | HYG | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Fixed Income |
52-Week High | $216.02 | $81.32 |
52-Week Low | $166.42 | $78.72 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
HYG trades at $79.52, down 0.24% with a bearish technical outlook indicated by 17 sell signals against 2 buy signals. The ETF maintains dividend distributions, with recent payouts of $0.42 in May 2026 and $0.41 in June 2026. Market sentiment is cautious amid Federal Reserve uncertainty and elevated put volume in high-yield bonds, reflecting investor concerns about interest rate hikes and inflation pressures.
Outlook remains challenged by macroeconomic headwinds and potential Fed tightening, though dividend yield provides income support. Key risks include interest rate volatility and narrowing market breadth. Investors should weigh yield attractiveness against duration risk in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
